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Abstract 
Biomaterial-associated infection is one of the most common complications related 
with the implantation of any biomedical device. Several in vivo imaging platforms have 
emerged as powerful diagnostic tools to longitudinally monitor biomaterial-associated 
infections in small animal models. In this study, we directly compared two imaging 
approaches: bacteria engineered to produce luciferase to generate bioluminescence 
and reactive oxygen species (ROS) imaging of the inflammatory response associated 
with the infected implant. We performed longitudinal imaging of bioluminescence 
associated with bacteria strains expressing plasmid-integrated luciferase driven by 
different promoters or a strain with the luciferase gene integrated into the 
chromosome. These luminescent strains provided adequate signal for acute (0-4 days) 
monitoring of the infection, but the bioluminescence signal decreased over time and 
leveled off by 7 days post-implantation. This loss in bioluminescence signal was 
attributed to changes in the metabolic activity of the bacteria. In contrast, near-
infrared fluorescence imaging of ROS associated with inflammation to the implant 
provided sensitive and dose-dependent signals of biomaterial-associated bacteria. ROS 
imaging exhibited higher sensitivity than the bioluminescence imaging and was 
independent of the bacteria strain. Near-infrared fluorescence imaging of 
inflammatory responses represents a powerful alternative to bioluminescence imaging 
for monitoring biomaterial-associated bacterial infections. 
 
Keywords: Biomaterial-associated infection; Bioluminescence; Near infrared 
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1. Introduction 
Device-related bacterial infections are a growing healthcare problem [1–3], 
accounting for more than 50% of the 2,000,000 annual hospital-acquired infections 
associated with indwelling devices and implants in the United States [2]. 
Staphylococcus aureus is one of the most common pathogens associated with these 
cases. Bacterial colonization and biofilm development can lead to both malfunction of 
the device and systemic infection, since biofilms are complex cooperative 
communities, and such biofilm bacteria are nearly impervious to antimicrobial therapy 
or host defense mechanisms [4,5]. In most cases, the affected devices must be 
removed to eliminate the infection, given the fact that currently there are no drugs 
that specifically target bacteria in biofilms [6–8].  
A requirement to efficiently treat implant-associated infections are in vivo 
monitoring approaches that allow better understanding and control of biofilm 
formation, together with novel methods for targeting efficient drug candidates [9]. 
Optical imaging of bacterial infections in vivo using engineered bioluminescent 
bacterial strains is a widely used approach for spatial and temporal assessment of the 
infection [10]. This method is based on bioluminescent bacteria expressing a 
luciferase-based reporter system that emits light that can be monitored longitudinally 
and nondestructively in the same animal.  
In view of the fact that biomaterial-associated infections modulate the 
inflammatory response to the biomaterial, changes in inflammatory markers may be 
used to improve monitoring of an ongoing infection [11]. In particular, reactive oxygen 
species (ROS) form part of the oxygen-dependent bactericidal mechanisms that 
4 
 
phagocytic cells employ [12]. Near-infrared fluorescence (NIRF) imaging probes, such 
as hydrocyanines, allow real-time fluorescence imaging and ROS detection in the 
vicinity of an implant [13]. Moreover, NIRF imaging is an excellent noninvasive method 
for whole-body scanning that can determine the extent of the infectious disease 
throughout the body, especially in clinically challenging cases involving trauma, 
infection, and compromised tissue beds. 
Herein, we directly compared two imaging approaches of implant-associated 
infection: bacteria engineered to produce luciferase to generate bioluminescence and 
ROS imaging of the inflammatory response associated with the infected implant. These 
approaches were correlated to bacterial counts before and after 7 days of 
implantation (Fig. 1).   
 
2. Materials and methods 
2.1. Disk fabrication 
Poly(3-hydroxyoctanoate-co-hydroxyhexanoate), PHOHHx, was kindly provided by 
Bioplolis S.L. The monomer composition of PHOHHx was determined by gas 
chromatography-mass spectrometry (GC-MS) as previously described [14] and 
consisted in 8.5% 3-hydroxyhexanoate (OH-C6) and 91.5% 3-hydroxyoctanoate (OH-
C8). An optimized downstream processing was applied to eliminate endotoxins as 
previously described [15]. Briefly, 1 g of PHOHHx was dissolved in 100 mL of 
chloroform at 40 °C under vigorous stirring, the suspension was pressure filtered and 
the polymer was precipitated by addition of non-solvent methanol. Finally, the 
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polymer was dried under vacuum at 40 °C for 48 h. This procedure was repeated two 
times to obtain PHOHHx with endotoxin units (EU) <20 EU g–1, in compliance with the 
endotoxin requirements for biomedical applications (FDA) [16]. The endotoxin content 
was measured using a Limulus amebocyte lysate (LAL)-test (Pyrogent Plus Single Test 
Kit, Lonza) and the endotoxin content was determined to be <15 EU g–1.  
Poly(ethylene terephthalate) (PET) disks (6 mm diameter) were coated with 
PHOHHx by solvent-casting. PHOHHx dissolved in chloroform (2% w/v) was applied 
over sterile, endotoxin-free PET disks (kindly supplied by ACCIONA, Barcelona, Spain), 
in a dust-free atmosphere. The coatings were allowed to dry for 72 h at room 
temperature and the resulting PHOHHx-coated disks (referred to hereafter as PHOHHx 
disks) were sterilized with ethylene oxide at 40 °C. 
 
2.2. Bacterial strains, media and growth conditions  
The bacterial strains used throughout this study were Staphylococcus aureus subsp. 
aureus ATCC 12600, its two derivate luminescent strains S. aureus (pAmiBlaz) and S. 
aureus (pAmiSPA), and the S. aureus Xen29 strain containing lux operon stably inserted 
into the chromosome (Caliper Life Sciences, PerkinElmer Company). All bacterial 
strains were pre-cultured in trypticase soy agar (TSA) plates and incubated at 37 °C for 
24 h. The appropriate selection antibiotics, chloramphenicol (10 µg mL–1) or kanamycin 
(200 µg mL–1), were added when indicated. Trypticase soy broth (TSB, Difco) was used 
as the growth medium to culture all bacterial pathogens.  
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2.3. Construction of S. aureus luminescent strains  
Bioluminescent S. aureus strains were generated by transforming ATCC 12600 strain 
with a modified Photorhabdus luminescens luxCDABE (lux) gene cluster using the 
pAmiBlaz or pAmiSPA plasmids. To construct the vectors, blaZ (β-lactamase) and spa2 
(protein A) promoters were inserted into promoterless-lux cloning vector pAmilux [17] 
to yield pAmiBlaz or pAmiSPA plasmid, respectively. Vectors were introduced into the 
cells by electroporation as previously described [18]. Transformants were selected on 
TSA plates containing chloramphenicol (10 µg mL–1). Successful transformation was 
confirmed by bioluminescent colonies screening using an IVIS Lumina bioimaging 
system (Xenogen). 
Expression of lux operon in pAmiBlaz vector was driven by the BlaZ promoter, 
whereas in pAmiSPA the lux operon was controlled by the protein A promoter. These 
two promoters were used with the aim to generate different expression patterns. The 
BlaZ promoter was used for constitutive expression of luciferase. In contrast, the S. 
aureus protein A is involved in the development of biofilm-associated infections [19]; 
therefore the spa promoter drives the expression of luciferase during biofilm 
development. S. aureus Xen29 (Caliper, PerkinElmer) is a commonly used, 
commercially available strain containing luciferase construct stably integrated into the 
chromosome.  
 
2.4. Preparation of hydro-indocyanine green  
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Hydro-indocyanine green (H-ICG) was synthesized from indocyanine green dye (ICG) 
(Acros Organics) by reduction with sodium borohydride as described [13]. Briefly, 2 mg 
of ICG was dissolved in 4 mL of methanol and reduced with 2-3 mg of sodium 
borohydride (Aldrich). Solvent was removed by stirring reaction mix for 5 min under 
reduced pressure.  The dye was nitrogen capped and stored overnight at -20 °C. 
 
2.5. Sample preparation, implantation and bioimaging  
    To test the biofilm formation of the S. aureus parental strain and its bioluminescent 
derivatives in vivo, bacterial strains were first cultivated overnight in TSB with aeration 
at 37 °C. The cultures were diluted with fresh TSB to reach absorbance A595 = 0.1 and 
incubated for 3-4 h to A595 = 0.7. Afterwards, bacterial test inocula were prepared in 2 
mL of phosphate-buffered saline, pH 7.2 (PBS), to serve as a cell suspension. Bacterial 
suspensions (3.5 x 102 to 3.5 × 108 CFU/mm2) were placed on sterile endotoxin-free 
PHOHHx disks. Prior to implantation, disks pre-colonized with bacteria were placed in 
sterile containers and incubated 30 min under static conditions at 37 °C.  
National Institutes of Health (NIH) guidelines for the care and use of laboratory 
animals were followed [20]. All surgical procedures were approved by the Institutional 
Animal Care and Use Committee at the Georgia Institute of Technology. Sterile, 
endotoxin-free disks as well as bacteria pre-colonized disks were implanted 
subcutaneously in the back of 6-8 weeks old male BALB/c mice (Jackson Laboratories) 
anesthetized by isofluorane. A single 1 cm incision was made on the dorsum proximal 
to the spine, and a subcutaneous pocket laterally spanning the dorsum was created. 
Sterile disks (two per mouse, one on either side of the spine) were implanted, and the 
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incision was closed using sterile wound clips. For analysis of each experimental group, 
3 or more mice were imaged. 
For bioimaging of luminescent bacteria, mice were anesthetized with isofluorane 
and imaged with a CCD camera (IVIS Lumina® bioimaging system, Xenogen) directly 
following implantation and 1, 4, 7 days post implantation. Bioluminiscence was 
integrated using Living Image® software Version 3.1 (Xenogen). Total counts from S. 
aureus were collected during a 2 min exposure using the IVIS Imaging System and 
Living Image software (Xenogen Corporation). Bioluminescence images were displayed 
using a pseudo-color scale (blue representing the least-intense light and red 
representing the most-intense light) that was overlaid on a gray-scale image to 
generate a two-dimensional image of the distribution of bioluminescent bacteria in the 
animal. To account for the background luminescence, one uninfected mouse was 
imaged along with the infected animals. The total counts from a region were 
quantified using the Living Image software package (Xenogen Corporation), and the 
data are presented as total counts contained within each region. 
For bioimaging of ROS, 30 µL of H-ICG at a concentration of 1 mg mL–1 in sterile 
water was injected near the vicinity of the implant as described [13]. The same animals 
used to image bioluminescence were used to evaluate NIRF signals. Thirty minutes 
after dye injection, the whole body of the animal was scanned in an IVIS Lumina® 
bioimaging system (Xenogen). Biofluorescence was integrated using Living 
Image®software Version 3.1 (Xenogen). ROS bioimaging was performed 7 days post- 
implantation. 
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2.6. Explant analysis 
After euthanasia, disks were carefully explanted with the intact surrounding tissue 
to avoid disrupting the cell-material interface. For immunostaining, explants were 
embedded in optimal cutting temperature compound (Tissue-Tek) and cryosectioned 
at 10 µm. Sections were fixed in 4% paraformaldehyde and stained with monoclonal 
antibodies (Abcam) against macrophage (CD68) or neutrophil (NIMP-R14) markers. 
Alternatively, samples were incubated with monoclonal antibodies against S. aureus 
(Abcam). AlexaFluor 488-conjugated goat antibody (Invitrogen) was used as a 
secondary antibody. The sections were mounted with antifade mounting media 
containing 4´,6-diamidino-2-phenylindole (DAPI, Vector Labs) and imaged under a 
Nikon C1 confocal microscope system. Five-six fields per sample were acquired and 
ImageJ software was used to count the fluorescently labeled cells.  
For CFU bacteria counting, each explant was placed in a glass tube containing 1 mL 
of PBS and sonicated for 10 min in an ultrasonic bath to remove adhered bacteria. 
Afterwards, two more sonicating cycles were applied (5 min and 30 s) interspersed 
with 30 s of vortexing. Serial dilutions were plated on TSA plates supplemented with 
kanamycin (50 µg mL–1) to determine the number of viable S. aureus Xen29 or 
chloramphenicol (10 µg mL–1) to determine the number of S. aureus carrying pAmiBlaZ 
or pAmiSPA. CFU were determined after 24 h of incubation at 37 °C. 
 
2.7. Statistical analysis  
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Statistical analysis was performed by two-way ANOVA using Tukey post-hoc test with P 
≤ 0.05 considered signiﬁcant. Pair-wise comparisons were performed using Bonferroni 
post-hoc test with P ≤ 0.05 considered signiﬁcant. 
 
3. Results 
3.1. Bioluminescent S. aureus permits short-term monitoring of Biomaterial-Associated 
Infections   
To monitor infection profile in an in vivo murine model, PHOHHx polymer disks 
were loaded with bioluminescent S. aureus strains carrying different genetic 
configurations of the lux operon. S. aureus (pAmiBlaz) and S. aureus (pAmiSPA) 
contained the luciferase construct in an antibiotic-selective plasmid, whereas S. aureus 
Xen29 contained the luciferase gene integrated into the bacterial chromosome.  
PHOHHx disks pre-colonized with different inocula of S. aureus luminescent strains 
were implanted subcutaneously in BALB/c mice and bioluminescent signal intensity 
was monitored over a 7-day period. For infected implants, the bioluminescence signal 
was significantly higher than readings for sterile PHOHHx implants (Fig. 2a,b). 
Bioluminescent signal for S. aureus (pAmiBlaz) and S. aureus (pAmiSPA) strains was 
detected only in a local site with high bacterial densities (3.5 x 106 - 3.5 x 108 
CFU/mm2), while lower bacterial densities did not emit detectable signal at any time 
point (Fig. 2a). The higher inocula, 3.5 x 107 and 3.5 x 108 CFU/mm2, of both strains had 
concentration-dependent increases in bioluminescent signals and showed maximal 
value 1 h post-implantation (Fig. 2b). Differences in bioluminescence levels due to 
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differences in promoter activity were evident. Over the next 4 days post-implantation, 
bioluminescent signal progressively decreased for both S. aureus (pAmiBlaZ) and S. 
aureus (pAmiSPA) strains, and only the highly expressed spa promoter provided 
detectable signal. At day 7 post-implantation, the bioluminescence signal for all strains 
was equivalent, although the signal was higher than sterile controls (Fig. 2b).  
Because bacterial luciferase is an energy-requiring oxygenase and as such a reporter 
of cell metabolic activity, it is likely that during the stationary phase of bacterial growth 
the intensity of luminescent signal is related to the cell metabolic activity rather than 
to the promoter activity. Additionally, the drop-off in signal could possibly be due to 
loss of the plasmid and/or reductions in bacteria numbers. The correlation between 
signal intensity and the number of bacteria containing plasmid was investigated by 
growing S. aureus (pAmiBlaz) and S. aureus (pAmiSPA) cells on the plates containing 
selective marker. CFU of bacteria carrying pAmiBlaz or pAmiSPA prior to implantation 
was compared with CFU of bacteria harboring plasmid up on disk retrieval on day 7. A 
decreased number of bacteria carrying plasmid was clearly observed (Fig. 3a) when 
grown on selective plates (see Materials and methods section for details), indicating a 
possible cause for the loss of bioluminescence signal.  
To examine whether the stable integration of the lux operon into the bacterial 
chromosome overcomes this limitation of the S. aureus (pAmiBlaz) and S. aureus 
(pAmiSPA) strains carrying the luciferase construct in a plasmid, we tested the S. 
aureus Xen29 strain. Using S. aureus Xen29, we were able to monitor the infection in 
the experimental model applying lower bacterial inoculums (3.5 x 103 and 3.5 x 104 
CFU/mm2) (Fig. 2a,b). Following implantation of pre-colonized disks, the 
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bioluminescence measurements increased exponentially over 24 h and peaked on day 
1 post-implantation (approximately 5.5 log (luminescence-total counts/disk) for 
bacterial inoculum 3.5 x 104 CFU/mm2 and 4.8 log (luminescence-total counts/disk) for 
bacterial inoculum 3.5 x 103 CFU/mm2). The high signal for Xen29 compared to the 
other strains is attributed to differences in the promoter and construct configuration. 
However, similar to our observations for the strains carrying the luciferase plasmid, the 
bioluminescence signal decreased at day 4 post-implantation and reached equivalent 
levels as the other bioluminescent strains by day 7 (Fig. 2b). Bacteria counts indicated 
significant loss in the number of viable bacteria at explant (Fig. 3b); this loss in viable 
bacteria is mostly likely due to an inflammatory response and accounts for the loss in 
bioluminescence signal. Taken together, these results demonstrate that bacteria 
strains expressing luciferase can be used to image infection short-term but none of the 
strains tested was suitable for monitoring chronic infections above a bacteria 
threshold (3.5 log CFU/mm2) in this model of biomaterial-associated infection.   
 
3.2. NIRF imaging of infection-associated inflammation 
We next applied NIRF imaging as a tool to examine biomaterial-associated 
infections using hydrocyanine dyes as an alternative to bioluminescent bacteria.  
Because inflammation patterns are a key correlate of the presence of an infection 
[21,22], the NIRF ROS sensor H-ICG was used to measure the levels of local 
inflammation associated with the infected biomaterial. Based on previous studies 
where biomaterial associated inflammation was longitudinally monitored using H-ICG 
[13,23], we observed the clearest evidence of NIRF signal at 7 days. Therefore, at 7 
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days post-implantation, H-ICG was injected in the vicinity of infected PHOHHx disks 
with a low bacteria inoculum (3.5 x 103 or 3.5 x 104 CFU/mm2) and animals were 
imaged in order to directly compare the two imaging modalities, NIRF and 
bioluminescence (Fig. 4). Increases in bacteria dose were clearly detected by imaging 
ROS via H-ICG signal, and these levels were significantly higher than the ROS signal for 
inflammation associated with sterile implants (Fig. 4b). Importantly, the H-ICG signal 
was independent of the bacteria strain used. In contrast, these lower bacteria densities 
were undetectable by imaging of bioluminescence (Fig. 5). NIRF imaging of infection-
related inflammation using H-ICG provided readings that correlated with bacterial 
concentration independently of the S. aureus strain used (Fig. 4b; Fig. 5).  
 
3.4. ROS signal correlate with inflammatory cell recruitment of infected biomaterials 
We analyzed macrophage (CD68) and neutrophil (NIMP-R14) recruitment to the 
implant at day 7 post-implantation by immunostaining (Fig. 6a-f). Both macrophages 
and neutrophils were recruited to the implant. Quantification of the number of cells 
staining for these markers revealed an increasing trend in neutrophil and macrophage 
recruitment with increased bacteria dose (Fig. 6g).  
Sections were also stained for S. aureus using a commercial antibody. Grape-like 
clusters, characteristic for Staphylococcus species, stained positive for S. aureus were 
widely present in all samples that were pre-colonized by bacteria prior to implantation 
(Fig. 7). Bacterial cells were observed only in the vicinity on contaminated implants and 
not surrounding tissues (SFig. 1), demonstrating the pattern of localized infection. 
Additionally, initial signs of tissue damage around infected implants became evident 
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with increasing number of bacteria used to pre-colonize disks. Tissue necrosis was 
present for inoculums of 3.5 x 108 CFU/mm2 or higher. DAPI-stained nuclei lost sharp 
borders and were completely destroyed (Fig. 7d,h). This phenomenon was observed 
only in the near vicinity of contaminated implant, whereas the cells of tissue located 
farther from the implant did not show signs of cell death (SFig. 1).   
 
4. Discussion 
Implantation of biomedical devices facilitates infection, since the biomaterial 
provides a surface for bacterial colonization and biofilm formation. Upon implantation, 
proteins and other biomacromolecules immediately coat the device and promote 
bacteria adhesion [24,25]. S. aureus harbors numerous cell wall-bound surface 
proteins that contain binding domains for mammalian proteins [26]. Early detection of 
these infections prior to formation of a recalcitrant biofilm is of great clinical 
importance. Hence, there is compelling need for the development of new sensitive 
diagnostic techniques for biomaterial-associated infections. 
Conventional methodologies for monitoring pathogens in vivo are cumbersome and 
include biological assessment such as biopsies, biochemical and genetic testing. 
Therefore, we focused on developing a minimally-invasive imaging strategy for in vivo 
monitoring of bacterial infection on polymeric implants. In this study, we directly 
compared two imaging approaches: bacteria engineered to produce luciferase to 
generate bioluminescence and ROS imaging of the inflammatory response associated 
with the infected implant. Bioluminescent bacteria strains are widely used in the field 
to study the progression of a bacterial infection. We performed longitudinal imaging of 
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bioluminescence associated with bacteria strains expressing luciferase plasmids driven 
by different promoters or a commercially available strain with the luciferase gene 
integrated into the chromosome. These luminescent strains provided excellent signal 
for acute (0-4 days) monitoring of the infection, but the bioluminescence signal 
decreased over time and leveled off by 7 days post-implantation (Fig. 2). We attribute 
this loss in bioluminescence signal primarily to changes in the metabolic activity of the 
bacteria. Because biofilm-associated bacteria mostly exist in a stationary phase-like 
state where transcription and translation are markedly reduced [4], we expect for 
luciferase expression to decrease as bacteria form biofilms. Notably, in one of the 
strains evaluated, luciferase was driven by the promoter of the spa2 gene responsible 
for expression of a S. aureus surface protein synthesized during biofim formation [20]. 
However, this construct did not increase the intensity of bioluminescence signal. 
Additionally, the decrease of number of bacteria carrying plasmid contributed to the 
loss of bioluminescence signal. The loss in bioluminescence signal was even observed 
when using a S. aureus strain carrying the lux operon stably integrated in the 
chromosome. In addition to the signal loss attributed to changes in metabolic activity 
in the bacteria, the intrinsic blue-green spectral output of lux (λmax = 425 nm) limited 
tissue penetration and the detection limit of this approach. Importantly, the 
magnitude and kinetics of luciferase expression were dependent on the specifics of the 
promoter and gene construct. Bioluminescence monitoring has been used as a tool to 
validate the efficiency of antibacterial treatment that implies short term screening 
[27,28]. Importantly, it has been reported that bioluminescence imaging could monitor 
chronic infection, but is strongly related to the infection model and bacterial strain 
used [29,30]. 
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As an alternative to bioluminescence imaging of luciferase-expressing bacteria, we 
evaluated NIRF imaging of ROS generated by the inflammation associated with 
bacterial infection. NIRF imaging offers excellent characteristics for optical imaging 
enabling deeper tissue penetration and sensitivity [31]. Indeed, several NIRF probes for 
in vivo imaging of bacterial infections have been reported [32-38]. The sensing 
mechanism for these probes is based on metabolic conversion of probe inside bacteria 
or molecules with high affinity for bacterial membrane proteins. As discussed 
previously, the metabolic activity in many bacterial species vary among planktonic and 
biofilm states, therefore limiting the wide applicability of these probes. In addition, 
many of these probes have not been validated for imaging biofilm associated with a 
biomaterial. In contrast, we show that the ROS sensor H-ICG could provide sensitive 
and dose-dependent signals of biomaterial-associated bacteria. In addition, ROS 
imaging exhibited higher sensitivity than the bioluminescence imaging. Importantly, 
the ROS signal was independent of the bacteria strain (Fig. 4); this is a major advantage 
over bioluminescence imaging because it does not require the use of a luciferase-
expressing bacteria strain. Additional characterization with other bacterial species and 
biomaterials is necessary to fully establish NIRF imaging of inflammatory responses as 
an effective strategy to monitor biomaterial-associated infections. Although the ROS 
signal for bacteria-colonized implants was significantly higher than the signal for sterile 
implants, the ROS probe would require calibration to discriminate between biofilm-
containing and sterile implants, and this calibration may vary significantly due to 
variability among patient, device, implant location, and biofilm characteristics. 
Nevertheless, NIRF imaging of inflammatory responses represents a powerful 
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alternative to bioluminescence imaging for monitoring biomaterial-associated bacterial 
infections in animal models. 
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Figure 1. Experimental timeline for comparison of bioimaging approaches of 
biomaterial-associated infection. PHOHHx disks were pre-colonized with engineered 
bioluminescent bacteria. Following counting bacteria and bioluminescence imaging, 
disks were implanted subcutaneously. Bioluminescence was measured at 0, 1, 4, 7 
days. After ROS imaging at day 7, disks were retrieved and analyzed for bacterial 
counts and immunostaining.    
 
Figure 2. Temporal progression of PHOHHx implant associated infection using different 
S. aureus luminescent strains. (a) Bioimaging data of animals scanned in an IVIS® 
imaging system for monitoring the intensity of S. aureus (pAmiBlaz), S. aureus 
(pAmiSPA) and S. aureus Xen29 luminescent signal. (b) Quantification of luminescence 
data from animals receiving subcutaneous PHOHHx implant pre-colonized with 
different S. aureus (pAmiBlaz), S. aureus (pAmiSPA) and S. aureus Xen29 CFU (n ≥ 3 
mice/time point). 
 
Figure 3. Quantification of plasmid-containing bacteria (a) and number of viable cells 
(b). (a) S. aureus cells containing pAmiBLAZ or pAmiSPA previous to implantation and 7 
days-post implantation was screened on TSA plates supplemented with 
chloramphenicol (10 µg mL–1). (b) The number of viable S. aureus Xen29 cells previous 
to implantation and 7 days-post implantation determined on TSA kanamycin (50 µg 
mL–1) plates. 
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Figure 4. NIRF imaging approach to detect PHOHHx implant-associated infection with 
different S. aureus strains at 7 days post-implantation. (a) Bioimaging data of animals 
scanned in an IVIS® imaging system for in vivo ROS imaging of inflammation associated 
with implant infection using H-ICG sensor. (b) Quantification of ROS fluorescence data 
from mice with PHOHHx implants incubated with 3.5 x 103 CFU/mm2 (open bars), 3.5 x 
104 CFU/mm2 (closed bars) and sterile PHOHHx implant (open black bar) (n ≥ 3 
mice/time point).  
 
Figure 5. Comparative representation of near IR fluorescence total efficiency (left axis) 
and bioluminescence total count (right axis) of S. aureus pre-colonized disks. NIRF 
imaging (bars) and bioluminescence imaging (line) of same S. aureus pre-colonized 
disks was compared in the same animals at 7 days post-implantation. 
 
Figure 6. Immunohistochemical staining for macrophages (CD68+) and neutrophils 
(NIMP-R14) in infected implant-associated inflammation. (a-c) Representative co-
localization images of CD68+ and DAPI stained nuclei in (a) sterile PHOHHx implant, (b) 
PHOHHx implant pre-colonized with 3.5 x 103 CFU/mm2, and (c) PHOHHx implant pre-
colonized with 3.5 x 105 CFU/mm2. (d-f) Representative co-localization images of 
NIMP-R14+ and DAPI stained nuclei in (d) sterile PHOHHx implant, (e) PHOHHx implant 
pre-colonized with 3.5 x 103 CFU/mm2 , and (f) PHOHHx implant pre-colonized with 3.5 
x 105 CFU/mm2. (g) Quantification of CD68+, NIMP-R14+ and total number of cells 
stained positive for CD68+ and NIMP-R14+ (n = 4 disks/bacterial concentration, *P < 
0.05). Scale bar 10 µm. 
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Figure 7. Immunochemical staining for (a-d) S. aureus (pAmiBLAZ) and (f-g) S. aureus 
(pAmiSPA) in PHOHHx implant associated infection. (a,e) Sterile PHOHHx implant, (b,f) 
3.5 x 106 CFU/mm2, (c,g) 3.5 x 107 CFU/mm2, and (d,h) 3.5 x 108 CFU/mm2. S. aureus 
marked with AlexaFluor 488-conjugated antibody shown in green, nucleus of cells 
surrounding implant DAPI stained and represented in blue. White arrows indicate 
zones of tissue necrosis. Scale bar 10 µm. 
 
Supplementary Figure 1. Detection of PHOHHx implant associated infection by 
immunohistochemical staining for (a-d) S. aureus (pAmiBLAZ) and (f-g) S. aureus 
(pAmiSPA) in areas located distally from implant. (a,e) Sterile PHOHHx implant, (b,f) 
3.5 x 106 CFU/mm2, (c,g) 3.5 x 107 CFU/mm2, and (d,h) 3.5 x 108 CFU/mm2. Scale bar 10 
µm. 
 
  
26 
 
 
 
27 
 
 
 
 
28 
 
 
  
29 
 
 
 
  
30 
 
 
 
31 
 
  
32 
 
 
 
  
33 
 
 
  
34 
 
 
35 
 
 
